奥曲肽联合奥美拉唑治疗肝硬化合并上消化道出血的临床效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Octreotide combined with Omeprazole in the treatment of cirrhosis complicated with upper gastrointestinal hemorrhage.Methods A total of 60 patients with cirrhosis complicated with upper gastrointestinal bleeding admitted to our hospital from September 2015 to April 2019 were selected as study subjects,and were divided into control group (30 cases)and experimental group (30 cases)according to the random number table method.Patients in the two groups were given routine symptomatic treatment,on the basis of which the control group was treated with Omeprazole alone,while the experimental group was treated with Octreotide combined with Omeprazole.The treatment course was 1 week in both groups.After the course of treatment,the overall effective rate,hemostasis time,rebleeding rate,hospitalization time and the improvement of inflammatory factors in the two groups were observed and compared,and the total incidence of adverse reactions during treatment was recorded.Results After treatment,the overall effective rate of the experimental group was 96.67%,which was higher than that of the control group(66.67%),and the difference was statistically significant(P＜0.05).The hemostasis time and hospital stay in the experimental group were shorter than those in the control group,the bleeding rate was lower than that in the control group,with statistically significant differences (P＜0.05).The total incidence of gastrointestinal spasm,nausea and vomiting,arrhythmia,palpitations and other adverse reactions in the experimental group was 10.00%,lower than that in the control group(33.33%),with statistically significant difference(P＜0.05).Procalcitonin(PCT)([0.24±0.04]ng/ml),C-reactive protein(CRP)([8.99±0.54]mg/L),interleukin-2(IL-2)([2.76±0.55]μg/ml)and interleukin-1 levels(IL-1β)([3.00±0.77]μg/ml)in the experimental group were lower than those in the control group for the levels of PCT([0.31±0.06]ng/ml),CRP([14.23±2.01]mg/L),IL-2([3.18±0.60]μg/ml)and IL-1β([3.62±0.96]μg/ml),the differences were statistically significant(P＜0.05).Conclusion Octreotide combined with Omeprazole can effectively eliminate inflammation,shorten hemostasis time,reduce rebleeding rate,shorten hospital stay and promote the recovery of patients with cirrhosis complicated with upper gastrointestinal bleeding under the premise of ensuring the safety of treatment.

Key words： Octreotide Omeprazole Combination therapy Cirrhosis of the liver Gastrointestinal hemorrhage

Received: 30 July 2019

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Qing-fang1 LIU Na1 XU Hong1 LI Jing-hua2

Cite this article:

HU Qing-fang1 LIU Na1 XU Hong1 LI Jing-hua2. Clinical effect of Octreotide combined with Omeprazole in the treatment of liver cirrhosis complicated with upper gastrointestinal bleeding[J]. 中国当代医药, 2020, 27(24): 87-90.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I24/87

[1]	杜登泰，付曼荣，杨刚，等.奥美拉唑联合奥曲肽治疗肝硬化并上消化道出血的疗效评价[J].现代消化及介入诊疗，2018，23（5）：99-101.
[2]	江海燕.血清铁蛋白、转铁蛋白、层粘连蛋白水平与肝硬化Child-Pugh分级的相关性分析[J].标记免疫分析与临床，2019，26（2）：285-289.
[3]	陈波.奥曲肽治疗肝硬化上消化道出血的疗效分析[J].局解手术学杂志，2010，19（3）：251-252.
[4]	黎勇强.凝血酶联合奥曲肽治疗肝硬化合并上消化道出血的临床分析[J].现代诊断与治疗，2015，26（18）：4169-4170.
[5]	罗青梅.奥美拉唑与奥曲肽联合治疗肝炎后肝硬化并上消化道出血的临床效果[J].深圳中西医结合杂志，2014，24（7）：81-82.
[6]	郝霞，刘洋.奥曲肽配伍凝血酶治疗肝硬化合并上消化道出血的临床疗效评价[J].临床医药文献电子杂志，2016，3（39）：7853.
[7]	Rauscher I，Eiber M，Ganter C，et al.Evaluation of T1ρas a potential MR biomarker for liver cirrhosis：comparison of healthy control subjects and patients with liver cirrhosis[J].Eur JRadiol，2014，83（6）：900-904.
[8]	王金锁.奥曲肽联合奥美拉唑钠治疗肝硬化合并上消化道出血的效果评价[J].现代诊断与治疗，2018，29（1）：1888-1890.
[9]	蒋丰娟，王文斌，喻群力.肝硬化并上消化道出血临床诊治分析[J].中外医疗，2017，36（21）：41-43.
[10]	李国珍，周锦霞.奥曲肽联合奥美拉唑治疗肝炎后肝硬化合并上消化道出血患者的疗效及对止血时间及不良反应的影响[J].实用临床医药杂志，2017，21（9）：49-51.
[11]	陈妤，田虹，黄晓丽，等.肝硬化合并非静脉曲张性上消化道出血临床分析[J].中山大学学报（医学科学版），2014，35（2）：278-283.
[12]	王芳，陈随才，曹娜娅.醋酸奥曲肽联合奥美拉唑治疗肝硬化门静脉高压所致上消化道出血的临床效果及对血流的影响[J].中国医学前沿杂志，2016，8（9）：133-136.
[13]	陈敏锋，邓启明，林颖华.奥曲肽联合奥美拉唑治疗肝硬化上消化道出血疗效的Meta分析[J].中国当代医药，2013，20（14）：167-169.
[14]	陈春，伍思国，杨智娟.肝硬化上消化道出血患者预后因素分析[J].实用肝脏病杂志，2015，18（3）：86-87.
[15]	杨美荣，邓莉莉，刘斌，等.生长抑素联合丹参治疗肝硬化并发上消化道出血与门静脉血栓形成的临床研究[J].中国现代医学杂志，2017，27（13）：63-66.
[16]	周光异，黄坤.浅析消化内镜治疗上消化道出血的临床效果[J].中国卫生标准管理，2017，8（17）：43-44.
[17]	王鹏，王波，南鹏，等.奥曲肽联合普萘洛尔治疗肝硬化上消化道出血的疗效及对血流动力学的影响[J].中国临床医生杂志，2019，47（3）：44-46.
[18]	羊海峰.奥曲肽联合奥美拉唑治疗肝硬化并上消化道出血的疗效分析[J].中外医学研究，2015，13（20）：46-47.
[19]	熊毅，胡昌琰.奥曲肽联合凝血酶治疗肝硬化上消化道出血患者分析[J].实用临床医药杂志，2018，22（22）：106-107，110.